ISRCTN50395346招募中未知
A double-blind randomised multi-centre, placebo-controlled trial of combined angiotensin converting enzyme-inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy in genetically characterised males with Duchenne Muscular Dystrophy without echo-detectable left ventricular dysfunction
ewcastle upon Tyne Hospitals NHS Foundation Trust (UK)0 个研究点目标入组 140 人开始时间: 2007年8月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Boys aged 7 to 12 years
- •2. Genetically confirmed DMD with normal left ventricular function on trans-thoracic echocardiography (i.e., left ventricular ejection fraction by Simpson's biplane method greater than 55% [normal mean + SD = 63 + 5%], no global or regional wall motion abnormalities)
排除标准
- •1. Contraindication to ACE-inhibitor or beta-blocker therapy
- •2. Patients, whose initial echo is of insufficient quality to allow reliable measurements of ejection fraction or wall motion
- •3. Patients with abnormal echocardiograms at baseline
- •4. Patients with abnormal renal function (creatinine greater than upper limit of local laboratory range; typically greater than 120 mmol/l) or consistently abnormally high serum potassium level (K greater than upper limit of local laboratory range; typically 5 mmol/l)
研究者
相似试验
进行中（未招募）
1 期
A double-blind randomised multi-centre, placebo-controlled trial of combined ACE-inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy in genetically characterised males with DMD without echo-detectable left ventricular dysfunction - DMD-Heart ProtectioMedDRA version: 9.1 Level: LLT Classification code 10013801 Term: Duchenne muscular dystrophyDuchenne muscular dystrophyEUCTR2007-005932-10-GBewcastle upon Tyne Hospitals NHS Foundation Trust85
进行中（未招募）
不适用
A multicentre, double-blind, randomised placebo-controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery. - Natriumbikarbonat-StudieCardiac surgical patients in whom the use of cardiopulmonary bypass is planned and having at least one ore more of the following risk factors for post-operative acute kidney injury• Age = 70 years• Preoperative plasma creatinine >120 µmol/L• Heart failure (NYHA class III / IV)• Insulin dependent diabetes mellitus• Valve surgery (with or without coronary artery bypass graft surgery)• Redo cardiac surgeryEUCTR2007-002223-32-DECharité Universitaetsmedizin402
进行中（未招募）
不适用
A multicenter, randomised double blind, placebo-controlled study of efficacy, safety and tolerability of Kaprolac® K301 for the treatment of seborrhoeic eczema (SE) of the scalp.seborrhoeic dermatitis of the scalpMedDRA version: 9.1Level: LLTClassification code 10039794Term: Seborrhoeic dermatitis capitisEUCTR2007-006188-59-SEMoberg Derma AB
进行中（未招募）
1 期
A MULTICENTRE CLINICAL STUDY TO EVALUATE THE EFFICACY ANDSAFETY OF IVERMECTIN IN PREVENTION OF COVID-19Prophylaxis of COVID-19 infectionMedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsEUCTR2021-001938-19-BGMedinCell S.A.400
进行中（未招募）
1 期
Safety, tolerability, efficacy and dose-response of GSK2831781 in ulcerative colitis.lcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-003278-28-BGGlaxoSmithKline Research & Development Limited320